Skip to product information
1 of 1

Elabscience

SKU:PKSV030335

Recombinant SARS-CoV-2 Spike RBD(E484Q)(His Tag)

Recombinant SARS-CoV-2 Spike RBD(E484Q)(His Tag)

Regular price $1,105.00 USD
Regular price Sale price $1,105.00 USD
Sale Sold out
Shipping calculated at checkout.
Size
Introducing the Recombinant SARS-CoV-2 Spike RBD(E484Q)(His Tag), a cutting-edge product designed to facilitate advanced research and development in the field of virology. This meticulously engineered recombinant protein offers a unique combination of the SARS-CoV-2 Spike Receptor Binding Domain (RBD) variant E484Q, coupled with a highly efficient His Tag for enhanced detection and purification capabilities.

Crafted with utmost precision, this product serves as an invaluable tool for scientists and researchers seeking to unravel the intricate mechanisms of the SARS-CoV-2 virus. The incorporation of the E484Q variant within the Spike RBD enables the investigation of its potential impact on viral infectivity, host receptor interactions, and immune responses, thereby contributing to a comprehensive understanding of the virus's behavior.

Furthermore, the inclusion of the His Tag in this recombinant protein facilitates streamlined purification processes, ensuring optimal yield and purity. This feature not only expedites experimental workflows but also enables accurate quantification and characterization of the protein, enabling researchers to delve deeper into its functional properties.

The Recombinant SARS-CoV-2 Spike RBD(E484Q)(His Tag) adheres to the highest quality standards, meticulously produced under stringent manufacturing protocols. Each batch undergoes rigorous quality control measures to guarantee consistency, reliability, and reproducibility, thereby instilling confidence in experimental outcomes.

With its exceptional attributes and unwavering commitment to scientific excellence, the Recombinant SARS-CoV-2 Spike RBD(E484Q)(His Tag) stands as an indispensable asset for virologists, immunologists, and researchers alike, propelling advancements in the fight against the ongoing global pandemic.
View full details